University of Coimbra   Report issue

Academic/Hospital Phase 3 Phase 4
Founded: Coimbra Portugal (1290)

Organization Overview

First Clinical Trial
2000
NCT00005583
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Assistant professor FMUC | Center of Neuroscience and Cell Biology, University of Coimbra, Portugal | Centro Hospitalar e Universitário de Coimbra, E.P.E. | Coimbra's University - Faculty of Medicine | Faculty of Psychology and Education Sciences, University of Coimbra | Health Sciences Research Unit: Nursing, Nursing School of Coimbra | Hospitais da Universidade de Coimbra | Hospitais da Universidade de Coimbra (HUC) | ICNAS - Institute of Nuclear Sciences Applied to Health | Institute for Occlusion and Orofacial Pain Faculty of Medicine, University of Coimbra | Instituto Politécnico de Coimbra | Nursing School of Coimbra | Nursing School of Coimbra (ESEnfC) | Universidade de Coimbra | University of Coimbra

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atherosclerosis (Phase 4)

Cardiovascular Diseases (Phase 4)

Colitis (Phase 4)

Colitis, Ulcerative (Phase 4)

Coronary Artery Disease (Phase 3)

Endometrial Neoplasms (Phase 3)

Plaque, Atherosclerotic (Phase 4)

Ulcer (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 15